Andy Hsieh
Stock Analyst at William Blair
(3.58)
# 2,203
Out of 5,060 analysts
361
Total ratings
41.3%
Success rate
4.2%
Average return
Main Sectors:
Stocks Rated by Andy Hsieh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics | Reiterated: Buy | n/a | $37.32 | - | 3 | Oct 6, 2026 | |
| NKTR Nektar Therapeutics | Reiterated: Buy | n/a | $35.78 | - | 32 | Oct 1, 2026 | |
| KLRA Kailera Therapeutics | Reiterated: Buy | n/a | $11.25 | - | 6 | Sep 30, 2026 | |
| TLX Telix Pharmaceuticals | Reiterated: Buy | n/a | $10.69 | - | 1 | Sep 22, 2026 | |
| VKTX Viking Therapeutics | Reiterated: Buy | n/a | $25.17 | - | 40 | Sep 22, 2026 | |
| CATX Perspective Therapeutics | Initiated Coverage: Buy | n/a | $2.17 | - | 1 | Sep 18, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | n/a | $4.52 | - | 17 | Sep 14, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $0.9011 | - | 19 | Sep 14, 2026 | |
| EXEL Exelixis | Reiterated: Buy | n/a | $62.23 | - | 60 | Sep 11, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Hold | n/a | $1.68 | - | 12 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $21.08 | - | 12 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.85 | - | 29 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.80 | - | 6 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.20 | - | 12 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.32 | - | 11 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $99.70 | - | 18 | Aug 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.84 | - | 14 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.3807 | - | 5 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.55 | - | 17 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.365 | n/a | 8 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.13 | n/a | 15 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.5592 | n/a | 22 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $156.19 | n/a | 1 | Feb 12, 2019 |
Enliven Therapeutics
Oct 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $37.32
Upside: -
Nektar Therapeutics
Oct 1, 2026
Reiterated: Buy
Price Target: n/a
Current: $35.78
Upside: -
Kailera Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.25
Upside: -
Telix Pharmaceuticals
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $10.69
Upside: -
Viking Therapeutics
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.17
Upside: -
Perspective Therapeutics
Sep 18, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $2.17
Upside: -
Corbus Pharmaceuticals Holdings
Sep 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.52
Upside: -
Cardiff Oncology
Sep 14, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.9011
Upside: -
Exelixis
Sep 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $62.23
Upside: -
Pyxis Oncology
Sep 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.68
Upside: -
Sep 8, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.08
Upside: -
Aug 31, 2026
Reiterated: Hold
Price Target: n/a
Current: $4.85
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.80
Upside: -
Aug 12, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.20
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.32
Upside: -
Aug 8, 2026
Reiterated: Hold
Price Target: n/a
Current: $99.70
Upside: -
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $4.84
Upside: -
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.3807
Upside: -
May 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.55
Upside: -
Jul 23, 2025
Rated: Hold
Price Target: n/a
Current: $0.365
Upside: n/a
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $1.13
Upside: n/a
Dec 1, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.5592
Upside: n/a
Feb 12, 2019
Reiterated: Buy
Price Target: n/a
Current: $156.19
Upside: n/a